NCT00542919 2020-10-19
A Study for Patients With Non-Hodgkin's Lymphomas
Eli Lilly and Company
Phase 2 Completed
Clinical Trials
11 trialsNCT00744991 2020-10-19
A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma
Eli Lilly and Company
Phase 2 Completed
NCT01432951 2020-10-12
A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma
Eli Lilly and Company
Phase 1 Completed
NCT00718419 2020-09-03
A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma
Eli Lilly and Company
Phase 2 Completed
NCT00042666 2020-08-10
A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.
Eli Lilly and Company
Phase 2 Completed
NCT00436280 2020-08-06
Chemotherapy for Participants With Lymphoma
Eli Lilly and Company
Phase 2 Completed
NCT00451178 2020-07-21
A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only
Eli Lilly and Company
Phase 2 Completed
NCT00088205 2020-07-01
Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma
Eli Lilly and Company
Phase 2 Completed
NCT01388335 2020-07-01
A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin
Eli Lilly and Company
Phase 1 Completed
NCT00475644 2018-11-05
A Study of Enzastaurin in Participants With Follicular Lymphoma
Eli Lilly and Company
Phase 2 Completed
NCT00332202 2018-09-10
PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin
Eli Lilly and Company
Phase 3 Completed